pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 7·1 min read
save

Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn

Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.

May 7, 2026·read at onclive ↗

Gender Differences in Bladder Cancer: Key TakeawaysWomen with bladder cancer face significant diagnostic delays because their symptoms are frequently misattributed to UTIs, often resulting in repeated antibiotic courses instead of urologic referral.Anatomical and biological differences between men and women contribute to disparate prevalence and presentation.Early detection, patient advocacy, and genetic testing are the pillars of improving outcomes for women with bladder cancer.

source

Reporting by onclive.

read at onclive ↗
62 words · retrieved May 7
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Oncology6

related stories

  • Apr 27Erasca reports RAS cancer drug data after legal threat from RevolutionEndpoints
  • Apr 27Revolution Medicines threatens to sue Erasca over patent, efficacy claimsEndpoints
  • Apr 27Lilly to buy startup Ajax in bid for a better JAK drugBioPharma Dive
  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEndpoints